# ViiV Healthcare: Phase 1 study closed enrollment, 107 enrolled (HIV Infections)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | ViiV Healthcare |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV |
| NCT ID | NCT07053384 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | HIV Infections |
| Intervention types | biological, drug |
| Target enrollment | 107 |
| Site countries | United States, Belgium, Denmark, Netherlands, Spain, United Kingdom |
| Posted | 2025-07-08 |
| Planned start | 2025-07-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 107 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07053384). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.